Skip to main
ACTU

ACTU Stock Forecast & Price Target

ACTU Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actuate Therapeutics is well-positioned for future success due to its promising lead asset, elraglusib, which has shown activity in a variety of preclinical and clinical settings, including pediatric cancers and mPDAC. The company's strong financials, with $13.1M in cash and equivalents expected to support operations into 2026, and multiple opportunities for non-dilutive funding through Rare Pediatric Disease Designations and potential Priority Review Vouchers, provide a favorable outlook for development and commercialization of elraglusib. Additionally, the upcoming regulatory discussions with the FDA and EMA, along with the company's plans for a global Phase 3 registrational study, further demonstrate its commitment to advancing this promising drug candidate. Overall, the potential for elraglusib to address unmet medical needs, its versatility in multiple tumor types, and compelling clinical data support a positive outlook for Actuate Therapeutics.

Bears say

Actuate Therapeutics is a high-risk investment due to its clinical stage, reliance on a single drug in development, and lack of significant revenue generation. Additionally, the company has a high cash burn rate, with a significant portion of their cash coming from license revenues from a related party. This raises concerns about the sustainability of their operations and potential conflicts of interest. These factors suggest a negative outlook for Actuate Therapeutics' stock.

ACTU has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actuate Therapeutics Inc (ACTU) Forecast

Analysts have given ACTU a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACTU has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actuate Therapeutics Inc (ACTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.